Xin-Mu Li , Ning-Ning Zhang , Xiao-Ling Zhang , Nuo Liu , Cong-Yuan Xia , Xiong Yang , Hui-Qin Wang , Xu Yan , Shi-Feng Chu , Nai-Hong Chen , Zhen-Zhen Wang
{"title":"Protocadherin 10, a member of cadherin superfamily, increases stress-susceptibility in chronic unpredictable stress-treated rats","authors":"Xin-Mu Li , Ning-Ning Zhang , Xiao-Ling Zhang , Nuo Liu , Cong-Yuan Xia , Xiong Yang , Hui-Qin Wang , Xu Yan , Shi-Feng Chu , Nai-Hong Chen , Zhen-Zhen Wang","doi":"10.1016/j.pbb.2026.174158","DOIUrl":null,"url":null,"abstract":"<div><div>Depression is a debilitating disorder influenced by individual variation in stress susceptibility. The identification of stress-sensitive and stress-resistant phenotypes is critical for understanding its pathogenesis. We previously identified several proteins associated with these phenotypes, yet their functional roles remain unclear. Here, we investigated whether protocadherin 10 (PCDH10), a brain-enriched non-clustered protocadherin, underlies individual differences in stress susceptibility. Rats were subjected to chronic unpredictable stress and classified as stress-sensitive or stress-resistant individuals based on sucrose preference. We found that PCDH10 mRNA and protein levels were significantly downregulated in the medial prefrontal cortex of stress-sensitive rats but upregulated in stress-resistant rats compared to controls. Conversely, opposing expression patterns were observed in the hippocampus. Functional studies demonstrated that PCDH10 overexpression in the hippocampus promoted depression-like behaviors, whereas its knockdown exerted a protective, antidepressant-like effect. Our findings reveal PCDH10 as a key region-specific regulator of stress susceptibility. Targeted inhibition of PCDH10 in the hippocampus represents a promising new therapeutic strategy for depression.</div></div>","PeriodicalId":19893,"journal":{"name":"Pharmacology Biochemistry and Behavior","volume":"261 ","pages":"Article 174158"},"PeriodicalIF":2.5000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology Biochemistry and Behavior","FirstCategoryId":"102","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0091305726000134","RegionNum":3,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BEHAVIORAL SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Depression is a debilitating disorder influenced by individual variation in stress susceptibility. The identification of stress-sensitive and stress-resistant phenotypes is critical for understanding its pathogenesis. We previously identified several proteins associated with these phenotypes, yet their functional roles remain unclear. Here, we investigated whether protocadherin 10 (PCDH10), a brain-enriched non-clustered protocadherin, underlies individual differences in stress susceptibility. Rats were subjected to chronic unpredictable stress and classified as stress-sensitive or stress-resistant individuals based on sucrose preference. We found that PCDH10 mRNA and protein levels were significantly downregulated in the medial prefrontal cortex of stress-sensitive rats but upregulated in stress-resistant rats compared to controls. Conversely, opposing expression patterns were observed in the hippocampus. Functional studies demonstrated that PCDH10 overexpression in the hippocampus promoted depression-like behaviors, whereas its knockdown exerted a protective, antidepressant-like effect. Our findings reveal PCDH10 as a key region-specific regulator of stress susceptibility. Targeted inhibition of PCDH10 in the hippocampus represents a promising new therapeutic strategy for depression.
期刊介绍:
Pharmacology Biochemistry & Behavior publishes original reports in the areas of pharmacology and biochemistry in which the primary emphasis and theoretical context are behavioral. Contributions may involve clinical, preclinical, or basic research. Purely biochemical or toxicology studies will not be published. Papers describing the behavioral effects of novel drugs in models of psychiatric, neurological and cognitive disorders, and central pain must include a positive control unless the paper is on a disease where such a drug is not available yet. Papers focusing on physiological processes (e.g., peripheral pain mechanisms, body temperature regulation, seizure activity) are not accepted as we would like to retain the focus of Pharmacology Biochemistry & Behavior on behavior and its interaction with the biochemistry and neurochemistry of the central nervous system. Papers describing the effects of plant materials are generally not considered, unless the active ingredients are studied, the extraction method is well described, the doses tested are known, and clear and definite experimental evidence on the mechanism of action of the active ingredients is provided.